Pathfinder Cell Therapy (PFND) Annual Balance Sheets

Annual · GAAP · USD millions
Access PFND quarterly Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Pathfinder Cell Therapy.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2014)
(Dec 31 2013) (Dec 31 2012) (Dec 31 2010)
Assets
Cash & cash equivalent0.03
Cash & Short-term Investments0.00
Accounts receivable0.00
Inventories0.00
Prepaid Expense, Current AS0.05
Total Current Assets0.07
Intangible Assets0.03
Total Assets0.11
Liabilities
Accounts Payable, Current AC0.23
Accrued Liabilities, Current AC0.84
Convertible Notes Payable, Current NO0.03
Other Liabilities, Current4.95
Total Current Liabilities6.05
Long-term debt0.00
Total Long-term Debt0.00
Total Liabilities6.05
Stockholders' Equity
Common Stock Value0.67
Additional Paid In Capital Common Stock11.83
Retained Earnings / Accumulated Deficit-18.44
Other Equity0.00
Common Stockholder's Equity-5.94
Total Stockholder's Equity-5.94
Liabilities & Stockholder's Equity0.11
4 historic quarters locked

Sign in to unlock the full Pathfinder Cell Therapy balance sheet history.

About PFND Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License